SHL is primed to exhibit at the Prefilled Syringe Seminar in Tokyo.
Taking place from 21-22 May, visitors are welcome to stop by SHL’s stand to learn more about its innovations and industry leading offerings.
As a long-standing exhibitors at this annual exhibition, which is hosted by the Parenteral Drug Association (PDA) Japan Chapter, SHL is set on presenting its strong pipeline of auto-injectors designed for high-volume and high-viscosity drug formulations.
Top displays include the Bertha® auto-injector, which is developed to deliver highly viscous drugs in syringe volumes up to 2.25ml. The Maggie® auto-injector will also be available, which is built with Needle Isolation Technology (NIT®), an innovative solution that facilitates a cartridge-based architect while preventing sharps injuries.
SHL’s Molly® family includes Molly® 1ml, Molly® 2.25ml and Molly® C. It showcases SHL’s self-developed, preconfigured technology for faster development timelines.
The rise of protein drugs and biologics in recent years have called for higher demands in SHL’s drug delivery offerings.
Executive director of Business Development Mike Weng commented: “As a leading device manufacturer in the industry for 30 years, SHL is committed to innovation and research that advances our offerings in becoming biologics’ best partner. This year, other than catching up on some industry talks with familiar faces, we are looking forward to expanding ties with potential partners.”
Visit SHL at the Sola City Conference Center from 21/22 May, where its experts will be on site to connect with visitors.